SM
SGMO

SG3 Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

SG3 Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-32,800
Closed -$161K – 317
2022
Q3 		$161K Buy
+32,800
New +$168K 0.02% 209
2021
Q4 		– Sell
-10,000
Closed -$90K – 1257
2021
Q3 		$90K Buy
10,000
+7,500
+300% +$74.1K ﹤0.01% 874
2021
Q2 		$30K Buy
+2,500
New +$28.3K ﹤0.01% 957

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SG3 Management's SGMO Position: Q4 2022 in Review

SG3 Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2022, closing a stake of 32,800 shares — an estimated $161K sold.

SG3 Management first reported a position in SGMO in Q2 2021 and held it in 3 quarters. The position peaked at $161K in Q3 2022. 182 funds tracked by Wall St. Rank hold SGMO as of Q4 2022.

  • SG3 Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2022 after selling out during the quarter.
  • SG3 Management sold 32,800 SANGAMO THERAPEUTICS INC shares in Q4 2022, an estimated $161K.
  • SG3 Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2021 and held it in 3 quarters.
  • SG3 Management's SANGAMO THERAPEUTICS INC position peaked at $161K in Q3 2022.
  • 182 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2022.

Based on SG3 Management's 13F filing for Q4 2022, filed 14 Feb 2023.